MRNS Projected Dividend Yield
Marinus Pharmaceuticals Inc ( NASDAQ : MRNS )Marinus Pharmaceuticals is a pharmaceutical company focused on the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus. The U.S Food and Drug Administration approved the use of ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder in patients two years of age and older. Co. is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. 20 YEAR PERFORMANCE RESULTS |
MRNS Dividend History Detail MRNS Dividend News MRNS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |